News

Published on 22 Mar 2024 on GuruFocus.com via Yahoo Finance

Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...


Article preview image

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines, has reported an insider sale according to a recent SEC filing. Chief Scientific Officer & Chief Operating Officer Pad Chivukula disposed of 8,565 shares of the company on March 19, 2024.Pad Chivukulas transaction was executed at an average price of $35.01 per share, resulting in a total sale amount of $299,785.65. Following this transaction, the insider's direct ownership in Arcturus Therapeutics Holdings Inc stands adjusted as per the latest filings.Over the past year, Pad Chivukula has engaged in multiple transactions, selling a cumulative total of 93,565 shares and making no purchases of the company's stock.The insider transaction history for Arcturus Therapeutics Holdings Inc shows a pattern of sales by insiders over the past year, with 12 recorded sells and no insider buys during the same period.

Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells 8,565 SharesArcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells 8,565 Shares

On the valuation front, Arcturus Therapeutics Holdings Inc's shares were trading at $35.01 on the date of the insider's recent sale, giving the company a market capitalization of approximately $891.164 million.The stock's price-to-GF-Value ratio stands at 0.31, with a GuruFocus Value of $111.56, indicating that Arcturus Therapeutics Holdings Inc is currently categorized as a Possible Value Trap, Think Twice according to the GF Value metric.

NASDAQ.ARCT price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to...

We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this...

Insider Monkey · via Yahoo Finance 11 Dec 2024

Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights:...

Revenue: $41.7 million for Q3 2024, down from $45.1 million in Q3 2023. Operating Expenses: $52.4...

GuruFocus.com · via Yahoo Finance 8 Nov 2024

Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Report Preview: What...

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is set to release its Q3 2024 earnings on Nov 7,...

GuruFocus.com · via Yahoo Finance 6 Nov 2024

Arcturus Therapeutics Holdings Inc. (ARCT): Among the Worst ARK Stocks According...

We recently compiled a list of the 10 Worst ARK Stocks To Buy According To Short Sellers. In this...

Insider Monkey · via Yahoo Finance 24 Aug 2024

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call Transcript May 8, 2024 Ar...

Insider Monkey via Yahoo Finance 9 May 2024

Arcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their impressive 284%...

It might be of some concern to shareholders to see the Arcturus Therapeutics Holdings Inc. (NASDA...

Simply Wall St. via Yahoo Finance 29 Apr 2024

Arcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a biotechnology company focused on the discover...

GuruFocus.com via Yahoo Finance 28 Mar 2024

Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a biotechnology company focused on the discover...

GuruFocus.com via Yahoo Finance 22 Mar 2024

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript March 7, 2024 ...

Insider Monkey via Yahoo Finance 8 Mar 2024

Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

Shares of Arcturus Therapeutics Holdings Inc. ARCT have surged 73% in the past three months compa...

Zacks via Yahoo Finance 4 Mar 2024